Hypercholesterolemia
Conditions
Keywords
hypercholesterolemia, statin, compliance
Brief summary
The primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related costs during the 36 month.
Interventions
DRUGRosuvastatin
Sponsors
AstraZeneca
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* high cholesterol with an indication for cholesterol-lowering medication (statins)
Exclusion criteria
* contra-indications for statin therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative direct/indirect disease-related costs were compared applying a societal perspective | — |
| Costs include resource utilization for ambulatory, hospital, rehabilitative and nursing care, medication, physiotherapy, transportation, and productivity loss) | — |
Secondary
| Measure | Time frame |
|---|---|
| Achievement of the 1998 European LDL-C goal of <115 mg/dL (3.0 mmol/L) | — |
| Changes in the lipid profile and compliance with therapy. | — |
Outcome results
None listed